Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
NCT06164275
Recruiting
This phase II trial tests how well giving pembrolizumab followed by chemotherapy with doxorubicin, vinblastine and dacarbazine works to treat patients with classical Hodgkin lymphoma. Pembrolizumab is a type of drug called a "monoclonal antibody (mAb)" that uses the body's immune system to help fight and kill cancer cells. Chemotherapy drugs, such as doxorubicin, vinblastine and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Stanford Cancer Center, Stanford, California +3 locations
Conditions: Classic Hodgkin Lymphoma
Register for Updates
Radicle Clarity 24: A Study of Health and Wellness Products on Cognitive Function and Related Health Outcomes
NCT06294431
Recruiting
A randomized, double-blind, placebo-controlled direct-to-consumer study of health and wellness products on cognitive function and related health outcomes
Gender:
ALL
Ages:
Between 21 years and 105 years
Trial Updated:
03/31/2025
Locations: Radicle Science, Inc, Del Mar, California
Conditions: Cognitive Function
Register for Updates
Registry for Stage 2 Type 1 Diabetes
NCT06481904
Recruiting
Stage 2 Type 1 Diabates (T1D) is an early stage of T1D characterized by dysglycemia but not yet leading to clinical symptoms. Progression of the disease to Stage 3 (clinical T1D), leads to overt hyperglycemia requiring eventually exogenous insulin. TZIELD® (teplizumab-mzwv) has been approved to delay onset of stage 3 T1D, by the United States (US) Food and Drug Administration (FDA) for adults and children aged 8 years and older with Stage 2 T1D. The purpose of this study is to collect general... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/31/2025
Locations: University of Chicago Medical Center- Site Number : 8400017, Chicago, Illinois +21 locations
Conditions: Type 1 Diabetes
Register for Updates
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT06647498
Recruiting
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remt... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: University of Alabama in Birmingham, Birmingham, Alabama +34 locations
Conditions: Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Register for Updates
The Sweet Dreams Study - Accuracy of Sleep Trackers in Children
NCT06787378
Recruiting
The study aims to evaluate the accuracy of sleep trackers in children aged 2 to less than 18 years. Children undergoing polysomnography, the gold standard for assessing sleep quality and duration, at Arkansas Children's Hospital may be eligible to participate. Participants will be asked to wear sleep trackers on the day of their sleep test. The data collected from the sleep trackers will be compared with the polysomnography results to determine the devices' accuracy.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
03/31/2025
Locations: Arkansas Children's Hospital, Little Rock, Arkansas +1 locations
Conditions: Sleep
Register for Updates
The Impact of Low Glycemic Index Nutritional Shake on Glucose Regulation in Overweight and Obese Adults
NCT06856460
Recruiting
Low glycemic index nutritional shakes have clinically shown to improve post-prandial glycemic responses in acute laboratory control studies. However, there is limited information on how replacing meals with low-glycemic index shake could impact glucose regulation in free-living adults consuming their own diets. The present study aims to examine the impact of adding the SP Glucose-Assist shake to the breakfast of non-diabetic overweight and obese adults. Subjects: 40 non-diabetic adults aged 2... Read More
Gender:
ALL
Ages:
Between 25 years and 65 years
Trial Updated:
03/31/2025
Locations: Arizona State University 850 PBC, Phoenix, Arizona
Conditions: Hyperglycemia, Obesity Prevention
Register for Updates
Light Therapy Intervention in Individuals With Parkinson's Disease
NCT06916260
Recruiting
The study looks to investigate the effects that light therapy delivered to the frontal cortex could have on Parkinson's disease related symptoms ( both cognitive and motor). The therapy is a non invasive technique that deliverers low level wavelength light to the front part of the head for 12 minutes. for this study the therapy will be done 3 times a week for 6 weeks. To measure the potential effects on the therapy in Parkinson symptoms, we will do a set of cognitive and motor test before and af... Read More
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
03/31/2025
Locations: University of Delaware STAR Tower, Newark, Delaware
Conditions: Parkinson Disease
Register for Updates
Studies of Neuregulin/ERBB Signaling in Human Heart
NCT02820233
Recruiting
This study examines the role of the epidermal growth factor (EGF) receptor family and the EGF family of ligands in the regulation of non-myocytes isolated from the human heart.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Maine Medical Center, Portland, Maine
Conditions: Heart Disease, Vascular Disease, Heart Failure
Register for Updates
Marker Driven Selection of Patients for Prostate Biopsy and Management
NCT04240327
Recruiting
The purpose of this research study is to determine if the interpretation of multiparametric MRI (mpMRI) with an algorithm called habitat risk score (HRS) in combination with a panel of blood and urine biomarkers is more effective at detecting prostate cancer than standard of care interpretation of mpMRI with the Prostate Imaging Reporting and Data System (PIRADS).
Gender:
MALE
Ages:
Between 40 years and 85 years
Trial Updated:
03/31/2025
Locations: University of Miami, Miami, Florida
Conditions: PSA, Elevated PSA, Prostate Cancer
Register for Updates
Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone
NCT05033288
Recruiting
This study compares carbon ion therapy, surgery, and proton therapy to determine if one has better disease control and fewer side effects. There are three types of radiation treatment used for pelvic bone sarcomas: surgery with or without photon/proton therapy, proton therapy alone, and carbon ion therapy alone. The purpose of this study is to compare quality of life among patients treated for pelvic bone sarcomas across the world, and to determine if carbon ion therapy improves quality of life... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
03/31/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Bone Sarcoma, Chondrosarcoma, Chordoma, Ewing Sarcoma of Bone, Pelvic Rhabdomyosarcoma
Register for Updates
Cannabis, HIV and Mental Processing Systems
NCT05430490
Recruiting
This study employs novel methods to identify key determinants and consequences of concurrent HIV infection and regular cannabis use. This study will acquire extensive phenotype data from peripheral and brain markers of immune activation, brain structure, and neuropsychological performance (NP) in persons living with HIV (PLWH) receiving combination anti-retroviral therapy (cART) (80 regular cannabis users and 80 non-users) and HIV uninfected (HIV-) controls (80 regular cannabis users and 80 non-... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/31/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri +1 locations
Conditions: HIV Infections, Cannabis
Register for Updates
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929
Recruiting
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/31/2025
Locations: Massachusetts General Hospital ., Boston, Massachusetts +15 locations
Conditions: Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms
Register for Updates